Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

NIAID Awards Zepto Life Technology Up to $8.9 Million for Liquid Biopsy Platform

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at clpmag.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Zepto Life Technology received an $8.9 million contract from NIAID to develop a plasma cell-free DNA liquid biopsy platform for invasive fungal infections, aiming to enable faster diagnosis via a blood test and support FDA submission.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 2 sources have reported it between 11 Aug 2026 and 13 Aug 2026.

◆ ◆ The Wire takeaway

You can shift from slow fungal diagnostics to rapid blood-based testing as Zepto’s platform nears hospital deployment; your hospital microbiology lab market just opened to new rapid diagnostics.

◆ Coverage

2 sources · first reported 11 Aug 2026 · latest 13 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsliquid-biopsyfungal-infectionsdiagnosticsnih-fundingclinical-labs